1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250

Autor:	Luis Paz-Ares, Alexis B. Cortot, B. Sarholz, C. Ying, J. Ferrer-Playan, Federico Cappuzzo, J. Bolleddula, A. Kalapur, Thierry Berghmans, N. Reguart Aransay, Z. Jianying, Y. Shibata, A. Thomas, Y. Chen, C. Moulin, T. Yoshida, Nobuyuki Yamamoto
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty business.industry Internal medicine Medicine Phases of clinical research In patient Topotecan Hematology business Platinum resistant medicine.drug
Zdroj:	Annals of Oncology. 32:S1171
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.250
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1b90545e795f1fed7222e9e69ae37013 https://doi.org/10.1016/j.annonc.2021.08.250 Zobrazit plný text záznamu